Home β€Ί Stock analysis β€Ί SILO

Silo Pharma (SILO) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET

Updated Oct 15, 2026, 4:00 PM ET

What changed since yesterday

SILO ends flat (+0.0%) to $1.20, 3 down days in a row. Closed at $1.20, +0.00% vs the prior close of $1.20. Day range $1.15–$1.24, opened at $1.20.

Last close$1.20+0.00%
Day range1.15–1.24
Open1.20
Volume14.10K
52-week range1.10–10.43
Avg volume (20d)123.84K

SILO daily analysis β€” what happened

A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.

Oct 15, 2026 β€” SILO ends flat (+0.0%) to $1.20, 3 down days in a row
Oct 14, 2026 β€” SILO dips 1.6% to $1.20, a 52-week low
Oct 13, 2026 β€” SILO slides 18.1% to $1.22, a 52-week low
Oct 12, 2026 β€” SILO rises 1.4% to $1.49, 3 up days in a row
Oct 9, 2026 β€” SILO rises 1.4% to $1.47
Oct 8, 2026 β€” SILO rises 0.7% to $1.45
Oct 7, 2026 β€” SILO dips 0.7% to $1.44, a 52-week low
Oct 6, 2026 β€” SILO dips 2.7% to $1.45, a 52-week low
Oct 5, 2026 β€” SILO rises 2.2% to $1.49 on 1.9x normal volume
Oct 2, 2026 β€” SILO dips 2.8% to $1.46, a 52-week low on 13.0x normal volume

SILO latest news & SEC filings

Every SEC filing by or about SILO in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.

Oct 14, 2026 Β· Form 8-K β€” Major event / current report

Current report β€” a filing companies must make within 4 business days of a major event

Source: SEC EDGAR filing 0001213900-26-109457

Oct 2, 2026 Β· Form 8-K β€” Major event / current report

Current report β€” a filing companies must make within 4 business days of a major event

Source: SEC EDGAR filing 0001213900-26-106435

Aug 19, 2026 Β· Form 8-K β€” Major event / current report

Current report β€” a filing companies must make within 4 business days of a major event

Source: SEC EDGAR filing 0001213900-26-091783

Aug 17, 2026 Β· Form 8-K β€” Major event / current report

Current report β€” a filing companies must make within 4 business days of a major event

Source: SEC EDGAR filing 0001213900-26-090748

Aug 13, 2026 Β· Form 10-Q β€” Quarterly report

Quarterly report (unaudited financial statements for the quarter)

Quarter ended Jun 30, 2025:

Source: SEC EDGAR filing 0001213900-26-089085

Aug 13, 2026 Β· Form SCHEDULE 13G/A β€” Update to a passive 5%+ stake (13G)

Update to a passive 5%+ stake (13G)

Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.

Source: SEC EDGAR filing 0001213900-26-088836

Aug 6, 2026 Β· Form EFFECT β€” EFFECT filing

EFFECT filing

Source: SEC EDGAR filing 9999999995-26-002570

Aug 6, 2026 Β· Form 424B3 β€” Prospectus / supplement for an offering or resale

Prospectus / supplement for an offering or resale

An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.

Source: SEC EDGAR filing 0001213900-26-086219

Jul 31, 2026 Β· Form S-8 β€” Employee share plan registration

Registration of shares for employee stock plans (S-8)

Source: SEC EDGAR filing 0001213900-26-083957

Jul 24, 2026 Β· Form S-3 β€” Shelf registration (S-3)

Shelf registration (S-3) β€” lets the company sell securities over time

An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.

Source: SEC EDGAR filing 0001213900-26-081368

Jul 14, 2026 Β· Form D β€” D filing

D filing

Source: SEC EDGAR filing 0001213900-26-077974

Jul 13, 2026 Β· Form 8-K β€” Major event / current report

Current report β€” a filing companies must make within 4 business days of a major event

Source: SEC EDGAR filing 0001213900-26-077296

Jul 8, 2026 Β· Form SCHEDULE 13G β€” Passive stake (13G)

Passive stake (13G) β€” an investor reported owning more than 5%

Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.

Source: SEC EDGAR filing 0000929638-26-002570

Jun 30, 2026 Β· Form ARS β€” Annual report to shareholders

Annual report to shareholders

Source: SEC EDGAR filing 0001213900-26-073369

Jun 30, 2026 Β· Form DEFA14A β€” Additional proxy materials

Additional proxy materials

Source: SEC EDGAR filing 0001213900-26-073368

Things to know before you trade SILO

SILO market data (last 20 sessions)

DateOpenHighLowCloseVolume
Oct 15, 20261.201.241.151.2014.10K
Oct 14, 20261.221.261.201.2064.80K
Oct 13, 20261.411.431.101.22153.90K
Oct 12, 20261.471.491.421.4922.20K
Oct 9, 20261.441.481.391.4717.00K
Oct 8, 20261.431.451.371.4514.30K
Oct 7, 20261.431.461.411.4422.40K
Oct 6, 20261.501.501.401.4527.60K
Oct 5, 20261.351.511.301.49207.90K
Oct 2, 20261.501.571.451.461.15M
Oct 1, 20261.511.601.481.5044.20K
Sep 30, 20261.601.601.461.51205.60K
Sep 29, 20261.711.711.611.6129.00K
Sep 28, 20261.741.791.651.6522.70K
Sep 25, 20261.811.811.721.7520.10K
Sep 24, 20261.791.831.721.7524.60K
Sep 23, 20261.741.841.741.7744.40K
Sep 22, 20261.771.771.711.7242.90K
Sep 21, 20261.771.841.721.7564.40K
Sep 18, 20261.701.901.661.84282.00K

About Silo Pharma

Silo Pharma (SILO) is listed on the Nasdaq and classified by the SEC under β€œPharmaceutical Preparations”. Its business address is in SARASOTA, FL. State of incorporation: NV. Fiscal year ends December 31. SEC CIK 1514183.

SILO board of directors & executives

From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).

Directors

NameRoleLatest filing
Eric WeisblumChief Executive OfficerDec 16, 2025

Executive officers

NameTitleLatest filing
Eric WeisblumChief Executive OfficerDec 16, 2025

Recent insider buys & sales

DateInsiderTypeSharesPrice
Dec 15, 2025Eric WeisblumBuy2,500$0.42
Dec 15, 2025Eric WeisblumBuy2,500$0.41
Nov 21, 2025Eric WeisblumBuy1,000$0.37
Nov 20, 2025Eric WeisblumBuy1,000$0.37
Nov 19, 2025Eric WeisblumBuy4,500$0.41
Nov 18, 2025Eric WeisblumBuy7,500$0.40

SILO financials (annual, from XBRL filings)

Fiscal year endRevenueNet incomeDiluted EPSOperating cash flow
Dec 31, 2025$72.10K$-4.23M-0.50$-4.66M
Dec 31, 2024$72.10K$-4.39M-1.19$-3.83M
Dec 31, 2023$72.10K$-3.70M-1.20$-3.22M
Dec 31, 2022$72.10K$-3.91Mβ€”$-3.50M
Dec 31, 2021β€”$3.90M0.04$-2.28M

Latest balance sheet: total assets $5.95M, total liabilities $1.07M, cash $3.28M (as of Jun 30, 2026).

SILO earnings / results-day log

DateFilingClose that day
No 8-K earnings releases in recent filings.

Related stocks Β· Pharmaceutical Preparations

Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)

Popular today

Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)

More on SILO

Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.